AcertaPharma is a technology company.
AcertaPharma is a technology company.
AcertaPharma has raised $60.0M across 1 funding round.
AcertaPharma has raised $60.0M in total across 1 funding round.
AcertaPharma has raised $60.0M in total across 1 funding round.
AcertaPharma's investors include Frazier Healthcare Partners.
Acerta Pharma is a biopharmaceutical company specializing in oncology and hematology therapeutics, particularly leveraging covalent binding technology to develop targeted small molecule drugs.[1][2] As a member of the AstraZeneca Group, it focuses on precision medicines that address specific cellular errors in cancer and serious diseases like chronic lymphocytic leukemia (CLL), with key products including the BTK inhibitor acalabrutinib (approved in 2019 for CLL) and involvement in Bcl-2 and CD20 inhibitors.[1][2] It serves patients with blood cancers and other hemic system disorders, solving problems of uncontrolled cell growth by inhibiting critical targets like BTK, Bcl-2, and CD20 to improve treatment efficacy and outcomes.[2]
The company has demonstrated strong clinical momentum, with 52 clinical trials, multiple FDA-approved drugs (e.g., first approvals in 2013, 2016, and 2017), and ongoing Phase 3 studies for indications like CLL.[2] Its integration into AstraZeneca has accelerated global development and commercialization.
Acerta Pharma originated in the Netherlands as an independent biotech firm focused on innovative covalent binding technology for drug discovery, particularly in oncology.[1][3] Founded in the early 2010s, it gained early traction through breakthroughs in kinase inhibitors, leading to pivotal deals and its acquisition by AstraZeneca in 2016 for $7 billion upfront plus milestones—this marked a transformative moment, providing resources to advance its pipeline.[1] Key founders and leadership hailed from expertise in medicinal chemistry and oncology, emerging from the idea of exploiting irreversible covalent bonds for more potent, durable target inhibition in hard-to-treat cancers like CLL.[3]
Early milestones included rapid progression of acalabrutinib to approval and partnerships that validated its tech platform, evolving from a startup to a key AstraZeneca oncology asset.[1][2]
Acerta Pharma rides the wave of precision oncology, where targeted therapies exploit genetic mutations in cancers like CLL, aligning with trends in biomarker-driven treatments and covalent drug innovation.[1][2] Timing is ideal amid rising demand for BTK inhibitors post-imatinib era, fueled by market forces like aging populations, increasing blood cancer incidence, and regulatory support for accelerated approvals.[2][3] It influences the ecosystem by validating covalent platforms—now emulated by rivals—and contributing to AstraZeneca's leadership in hematology, pushing standards for durable responses in relapsed/refractory settings.[1]
Acerta's pipeline positions it for expansion in CLL and beyond, with ongoing Phase 3 trials (e.g., acalabrutinib combos) likely yielding new indications by 2026-2027.[2] Trends like combination therapies, next-gen covalent inhibitors, and AI-aided drug design will shape its path, potentially amplifying AstraZeneca's oncology dominance. Its influence may evolve toward broader autoimmune applications, solidifying covalent tech as a biotech cornerstone—echoing its origins as a precision medicine pioneer now scaled globally.[1][2]
AcertaPharma has raised $60.0M across 1 funding round. Most recently, it raised $60.0M Series A in March 2013.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Mar 1, 2013 | $60.0M Series A | Frazier Healthcare Partners |